A panel of four acquired neratinib-resistant HER2+ breast cancer cell lines (HCC1954-N, HCC1569-N, BT474-N, SKBR3-N) was investigated for the potential for the neratinib/dasatinib combination in models of neratinib-refractory disease. The gene discussed is ERBB2; the disease is breast carcinoma.